2.26
-0.03(-1.31%)
Currency In USD
| Previous Close | 2.29 |
| Open | 2.34 |
| Day High | 2.34 |
| Day Low | 2.22 |
| 52-Week High | 4.92 |
| 52-Week Low | 1.23 |
| Volume | 341,741 |
| Average Volume | 606,328 |
| Market Cap | 84.82M |
| PE | -0.97 |
| EPS | -2.33 |
| Moving Average 50 Days | 2.39 |
| Moving Average 200 Days | 2.03 |
| Change | -0.03 |
If you invested $1000 in Metagenomi, Inc. Common Stock (MGX) since IPO date, it would be worth $219.2 as of November 05, 2025 at a share price of $2.26. Whereas If you bought $1000 worth of Metagenomi, Inc. Common Stock (MGX) shares 1 year ago, it would be worth $219.2 as of November 05, 2025 at a share price of $2.26.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
GlobeNewswire Inc.
Aug 11, 2025 8:05 PM GMT
Dr. Reid brings 30 years of experience in building biotech companies based on innovative scientific platforms and shaping pipeline and business strategyEMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Compa
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
GlobeNewswire Inc.
May 14, 2025 10:00 AM GMT
- Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders - - Advancements demonstrate the ability to specifically inte
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
GlobeNewswire Inc.
May 13, 2025 8:30 PM GMT
- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximately 19 months with an encouraging safety profile - Well capitalized with $226.0 million in cash,